Why is routine prostate-specific antigen (PSA) screening not recommended?

Why Routine PSA Screening Is Not Recommended

Routine PSA screening is not recommended because the harms of overdiagnosis and overtreatment—including urinary incontinence, erectile dysfunction, and unnecessary anxiety—outweigh the modest mortality benefit for most men, particularly outside the 55-69 year age range. 1

The Core Problem: Overdiagnosis and Overtreatment

The fundamental issue with routine PSA screening is that most prostate cancers detected are indolent and would never cause symptoms or death during a man's lifetime 2. As noted in the 2018 NCCN guidelines, "the Achilles' heel of screening is overdetection and overtreatment of indolent tumors" 2. Despite driving mortality down by >50%, the cost was "too much in entirely avoidable treatment and its attendant side effects" 2.

Key Harms Include:

• Low specificity: Only 25% of men with elevated PSA actually have cancer (positive predictive value ~25%), meaning 3 out of 4 men with abnormal results undergo unnecessary worry and further testing 3
• Biopsy complications: 4% experience febrile infections, plus bleeding, pain, and hospital readmissions 3
• Treatment morbidity: Significant rates of urinary incontinence and erectile dysfunction from surgery or radiation 1
• Psychological burden: Anxiety and uncertainty from false positives and cancer diagnoses that may never require treatment 1

The Evidence on Mortality Benefit

The mortality benefit from screening is modest and uncertain:

• The European ERSPC trial showed a 21% relative risk reduction in prostate cancer death at 11 years, but this translates to preventing only 1 prostate cancer death per 1,000 men screened over a decade 4
• The U.S. PLCO trial found no mortality benefit and actually a non-significant increase in prostate cancer mortality in the screening group 5
• No study has shown any reduction in all-cause mortality 5, 6
• A 2010 systematic review of 6 randomized trials with 387,286 participants found no significant effect on prostate cancer death (RR 0.88,95% CI 0.71-1.09) or overall mortality 6

Age-Specific Considerations

The risk-benefit balance varies dramatically by age:

Men Under 55 Years

• Evidence for benefit is lacking 4
• Harms of overdiagnosis and overtreatment remain high 4
• The AUA 2013 guideline explicitly recommends against routine screening in men aged 40-54 at average risk 4

Men 55-69 Years

• This is the only age group where benefits may outweigh harms 4
• Even here, guidelines universally recommend shared decision-making, not routine screening 1
• The Canadian Task Force gives only a weak recommendation against routine screening even in this age group 1

Men 70+ Years

• Strong recommendation against screening 1
• The USPSTF 2018 explicitly recommends against screening men ≥70 years 1
• Men aged 75+ with PSA <3.0 ng/mL are unlikely to die of prostate cancer and may safely discontinue screening 7

The Shift from "Routine" to "Individualized"

All major guidelines now emphasize shared decision-making over routine screening 2, 1, 2, 1:

• USPSTF 2018: Changed from recommending against all screening to supporting individualized decisions for men 55-69 2, 1
• AUA 2015: Shared decision-making for ages 55-69; recommends against routine screening outside this range 1
• Canadian Task Force 2014: Recommends against routine screening (weak in 55-69, strong in other ages) 1

Historical Context: Why Screening Was Poorly Implemented

The 2018 NCCN guidelines acknowledge that in the 1990s-2000s, routine screening was poorly implemented with 2:

• Overscreening of older men who wouldn't benefit
• Underscreening of younger high-risk men (African Americans, family history)
• Overtreatment of low-risk disease that didn't need treatment
• Undertreatment of high-risk disease that did need aggressive therapy

Clinical Pitfalls to Avoid

1. Don't screen men with <10-15 year life expectancy regardless of age 1
2. Don't interpret PSA in isolation—consider age, ethnicity, family history, digital rectal exam 2
3. Don't automatically biopsy every elevated PSA—consider newer biomarkers (PHI, 4Kscore, PCA3) and multiparametric MRI to reduce unnecessary biopsies 2
4. Don't treat every detected cancer—active surveillance is appropriate for low-risk disease 2

The Bottom Line

"Routine" screening implies universal application without individualized assessment, which is precisely what the evidence does not support. The term "routine" is problematic because it suggests screening should be automatic, when in fact the decision requires careful weighing of modest benefits against substantial harms, consideration of individual risk factors, and informed patient preferences 1, 4, 1.